387 related articles for article (PubMed ID: 14639996)
1. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
2. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
[No Abstract] [Full Text] [Related]
3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
4. [Prevention by life style intervention and medication. To run away from type 2 diabetes].
Wepner U
MMW Fortschr Med; 2004 Apr; 146(14):16. PubMed ID: 15344745
[No Abstract] [Full Text] [Related]
5. [Cardioprotection by acarbose--contra].
Kaiser T; Sawicki PT
Dtsch Med Wochenschr; 2004 May; 129(20):1156. PubMed ID: 15143460
[No Abstract] [Full Text] [Related]
6. [Cardioprotection by acarbose--pro].
Breuer HW
Dtsch Med Wochenschr; 2004 May; 129(20):1155. PubMed ID: 15143459
[No Abstract] [Full Text] [Related]
7. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
8. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
Nishimura R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
[No Abstract] [Full Text] [Related]
9. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
10. [Study with alpha-glucosidase inhibitor proves: diabetes can be delayed].
MMW Fortschr Med; 2002 Aug; 144(33-34):57. PubMed ID: 12380153
[No Abstract] [Full Text] [Related]
11. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
12. [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].
Fölsch UR; Lembcke B
Internist (Berl); 1991 Dec; 32(12):699-707. PubMed ID: 1823561
[No Abstract] [Full Text] [Related]
13. Does intensive glycemic control improve cardiovascular outcomes?
Pendergrass M
Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
[No Abstract] [Full Text] [Related]
14. Opinion: Tight blood glucose control and cardiovascular disease in the elderly diabetic? Let the randomized controlled trials speak for themselves.
Sherman FT
Geriatrics; 2008 Aug; 63(8):8-10. PubMed ID: 18672951
[No Abstract] [Full Text] [Related]
15. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
16. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
17. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
18. [New, in Austria registered specialty drugs. Glucobay (acarbose)].
Sturm M
Wien Klin Wochenschr; 1992; 104(11):329-36. PubMed ID: 1621396
[No Abstract] [Full Text] [Related]
19. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
Ametov AS; P'ianykh OP; Chernikova NA
Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
[TBL] [Abstract][Full Text] [Related]
20. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
Schatz H
Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
[No Abstract] [Full Text] [Related]
[Next] [New Search]
